Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of filgotinib in perianal fistulizing Crohn's disease
MOH_2018-04-26_002338Phase 2Not yet recruiting
- Sponsor
- Gilead Sciences
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgotinib in Crohn's disease (3 arms), sponsored by Gilead Sciences. Primary endpoint: Combined fistula response. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
filgotinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-04-26_002338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-04-26_002338.